MedTrace Logo

Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients

NCT02666716 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2020-12-07

No results posted yet for this study

Summary

The pharmacokinetics of fluconazole are expected to be different in ICU patients compared to non-ICU patients. The investigators will determine fluconazole and free fluconazole concentrations in 20 ICU patients, who will get intravenous fluconazole as standard care. Switching to oral/enteral fluconazol is allowed after day 3.

A full pharmacokinetic curve will be taken on day 3 of iv therapy and limited pharmacokinetic curves on day 7 of iv therapy and/or on day 3 of oral therapy; trough levels will be taken daily after intravenous therapy.

Conditions

  • Candidiasis

Interventions

DRUG

fluconazole

Dose according to summary of product characteristics (SPC) or local protocols

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Roger Brüggemann, PharmD, PhD · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02666716 on ClinicalTrials.gov